Accellta specializes in large-scale production of embryonic and induced pluripotent stem cells, progenitors, and differentiated cells. These products are used in cell banking, drug discovery, regenerative medicine, and scientific research. The company uses 3D carrier-free suspension systems under feeder-free, adherent-free, and xeno-free conditions, optimizing production efficiency and reducing costs while maintaining consistent quality. Accellta's manufacturing facility adheres to Good Manufacturing Practice (GMP) guidelines, supporting industrial-scale cell banking and clinical batch production. The company’s patent portfolio covers media formulations and pluripotent stem cell culturing techniques, reflecting its focus on advancing cell culture technologies.